Wu Qitong, Nandi Deeptashree, Sharma Dipali
Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB 1, Rm 145, Baltimore, MD, 21231, USA.
Cancer Metastasis Rev. 2024 Dec 7;44(1):16. doi: 10.1007/s10555-024-10226-2.
While most Tripartite motif (TRIM) family proteins are E3 ubiquitin ligases, some members have functions beyond the regulation of ubiquitination, impacting normal physiological processes and disease progression. TRIM29, an important member of the TRIM family, exerts a predominant influence on cancer growth, epithelial-to-mesenchymal transition, stemness and metastatic progression by directly potentiating multiple canonical oncogenic pathways. The cancer-promoting effect of TRIM29 is also evident in metabolic interventions and interference with the efficacy of cancer therapeutics. As expected for any key node in cancer, the expression of TRIM29 is tightly regulated by non-coding RNAs, epigenetic modulation, and post-translational regulation. A systematic discussion of how TRIM29 is regulated in cancer, its influences on cancer progression, and its impact on cancer therapeutics is presented in this review. We also explore the context-dependent alterations between TRIM29 function from oncogenic to tumor suppression. As TRIM29 is involved in multiple aspects of cancer progression, a better understanding of its biological impact in cancer may help improve prognosis and develop novel therapeutic combinations, leading to improved personalized cancer care.
虽然大多数三聚体基序(TRIM)家族蛋白是E3泛素连接酶,但有些成员具有泛素化调节之外的功能,影响正常生理过程和疾病进展。TRIM29是TRIM家族的重要成员,通过直接增强多种经典致癌途径,对癌症生长、上皮-间质转化、干性和转移进展发挥主要影响。TRIM29的促癌作用在代谢干预和对癌症治疗疗效的干扰中也很明显。正如癌症中任何关键节点所预期的那样,TRIM29的表达受到非编码RNA、表观遗传调控和翻译后调控的严格调节。本综述系统讨论了TRIM29在癌症中的调控方式、其对癌症进展的影响及其对癌症治疗的影响。我们还探讨了TRIM29功能从致癌到肿瘤抑制的背景依赖性改变。由于TRIM29参与癌症进展的多个方面,更好地了解其在癌症中的生物学影响可能有助于改善预后并开发新的治疗组合,从而改善个性化癌症护理。